The Role of Adjuvant Therapy in the Management of Chronic Urticaria.

W Keumala Budianti, S Mahri, D Almira

Journal: Actas dermo-sifiliograficas 2023;114(6):523-530

PMID: 36871821

Free Full Text on Ediciones Doyma, S.L. View on PubMed

Abstract

Recent guideline on the management of urticaria recommends second-generation H1-antihistamine as the first-line therapy, with dose increases of up to fourfold if inadequately controlled. However, the treatment of chronic spontaneous urticaria (CSU) is often disappointing, so additional adjuvant therapies are needed to increase the effectiveness of first-line therapy, especially in patients who are refractory to the increase of antihistamine doses. Recent studies recommend various adjuvant therapy modalities for CSU, such as biological agents, immunosuppressants, leukotriene receptor antagonists, H2-antihistamine, sulfones, autologous serum therapy, phototherapy, vitamin D, antioxidants, and probiotics. This literature review was made to determine the effectiveness of various adjuvant therapies in managing CSU.

Address: Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo, Jakarta, Indonesia.; Department of Dermatology and Venereology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo, Jakarta, Indonesia. Electronic address: [email protected].

DOI: 10.1016/j.ad.2023.02.015

Link outs

Free resources

Full Text Sources:

https://www.elsevier.es/en/linksolver/pdf/pii/S000...

Medical:

https://medlineplus.gov/hives.html

MeSH Terms: Humans, Chronic Disease, Chronic Urticaria, Urticaria, Histamine H1 Antagonists, Combined Modality Therapy, Omalizumab